Jefferies Global Healthcare Conference
Logotype for Charles River Laboratories International Inc

Charles River Laboratories (CRL) Jefferies Global Healthcare Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for Charles River Laboratories International Inc

Jefferies Global Healthcare Conference summary

17 Nov, 2026

Strategic framework and efficiency

  • CEO introduced Pathway to Purpose, focused on modernization, portfolio refinement and client centricity to support competitiveness over the next 3 years, 5 years and beyond.

  • Create the Future targets $300M in cost savings over the next 3 years, following $300M taken out over the prior 3 years; expected margin improvement is ~75 bps over the next few years.

  • Modernization aims to make processes more scalable, automated and digital; an automated Microbial Solutions production line increased capacity 14%.

  • Apollo Orchestrate will digitize Biologics Testing workflows from sample submission through lab work and reporting, including data organization and AI use.

Portfolio and client relationships

  • Divested European early discovery assets and the CDMO business together with cell supply; acquired a non-human primate facility to integrate supply and support timely critical safety studies.

  • PathoQuest acquisition adds NAMs technology intended to replace in vivo testing in Biologics Testing and cell-bank characterization, reducing a normal 20-week process by 40%.

  • Signed a primary strategic partnership with a top-10 pharmaceutical company; leadership cited stronger client access and reliable service as priorities for long-term shareholder value.

Demand, pricing and growth outlook

  • Demand improved across biotech and global biopharma; proposal rates rose high-single to high-double digits YoY for five consecutive months, while book-to-bill gains spanned both client segments.

  • Early-stage funding and company formation remain areas to monitor; biotech funding was lower in Q3 but appeared stable again in Q4.

  • Pricing increases are beginning after strategic discounting during 2024-25; capture rates remained up, but revenue realization may take a few quarters as lower-priced backlog is worked through.

  • DSA long-range growth target is 5%-7%, based on visible demand and client pipelines; AI-driven demand and further pricing could add upside, while biotech funding remains a key risk to the range.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Charles River Laboratories